The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Commodities And Pharma Push FTSE 100 Below 6,000

Tue, 22nd Sep 2015 16:11

LONDON (Alliance News) - Stocks in London ended down Tuesday, with commodities-related stocks and pharmaceutical shares dragging down the FTSE 100, which ended below the 6,000 line for the first time in nearly a month.

The blue-chip index closed down 2.8% at 5,935.84 points, with all its constituents in the red except for RSA Insurance, which ended up 0.6%, a day after its shares tumbled 21% because Zurich Insurance pulled out of talks to buy the company.

The mid-cap FTSE 250 index declined 2.2% to 16,529.98, while the AIM All-Share ended down 1.3% at 730.51. European major indices also finished lower, with the CAC 40 in Paris down 3.4% and the DAX 30 in Frankfurt off 3.8%.

Shares in China closed higher as the Hang Seng index ended up 0.2% and the Shanghai Composite up 0.9%, while the Japanese market remained closed for holiday until Thursday.

In the US, stocks were in the red at the London close. The Dow Jones Industrial Average was down 1.7%, the S&P 500 down 1.7% and the Nasdaq Composite down 2.1%.

The strength of the dollar since the US Federal Reserve on Thursday last week decided to keep US interest rates on hold is hurting the price of commodities such as gold, silver and oil. The yellow metal retreated Tuesday to USD1,125.72 an ounce, while silver was down at USD14.79 per ounce.

The pound was lower against the dollar Tuesday at the London close, standing at USD1.5366, having traded at USD1.5558 before the Fed decision last week.

As a result, London-listed mining and oil-related stocks took yet another hit on Tuesday, with miners' misery exacerbated by a series of downgrades in the sector by Credit Suisse.

Antofagasta, down 6.6%, was cut to Underperform from Neutral, while Anglo American, 6.1%, was downgraded to Neutral from Outperform. Mid-cap KAZ Minerals, down 25%, was cut to Neutral from Outperform.

Others such as BHP Billiton, down 4.2%, and Rio Tinto, down 3.5%, also ended among the biggest fallers. Glencore was the worst performer in the FTSE 100, down 9.6% at 107.53 pence, having touched a new all-time low of 99.59p, the first time its price has gone below 100.00p.

Oil also was under pressure Tuesday. At the London close, Brent oil prices were down at USD47.85 a barrel, coming off the level of USD50.31 prior to the Fed announcement, while West Texas Intermediate stood at USD45.62 a barrel, having traded at USD47.68 before the Fed decision.

Oil stocks finished lower, with BG Group down 3.0%, Royal Dutch Shell 'B' shares down 3.1% and BP down 2.5%.

Outside of the commodities sector, London-listed pharmaceutical companies were out of favour after US presidential candidate Hillary Clinton tweeted about "price gouging" in the specialty drug market.

On her official Twitter account Monday, Clinton cited a New York Times article which said the price of the Daraprim drug, which treats a life-threatening parasitic infection, soared to USD750 a tablet from USD13.50 a tablet overnight.

Clinton, the frontrunner for the Democratic nomination, tweeted "price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on". Clinton was scheduled to make the announcement in Des Moines, Iowa, at 2 pm local time Tuesday, which is 2000 BST.

Shire ended down 5.0%, AstraZeneca down 4.4% and GlaxoSmithKline down 3.1%. The FTSE 100 drug makers all have significant US sales.

Engineering company GKN also was amongst the biggest fallers, down 6.1%, amid worries about knock-on effects of the emissions cheating scandal engulfing German car maker Volkswagen, the largest customer of GKN's Driveline business.

Though UBS said that the impact on GKN is likely to be "trivial", shares in the engineer touched a low it hasn't seen since early 2013.

Meanwhile, Johnson Matthey, the platinum group metals company that makes emission control technologies, lost 8.0%

Supermarket chain J Sainsbury ended down 1.6% even though Kantar Worldpanel's grocery market survey said that it was the only big four UK supermarket to increase sales in the past 12 weeks, for the second consecutive period.

Sainsbury's sales rose 0.9% in the 12 weeks to September 13 to GBP4.01 billion from GBP3.97 billion in the same period a year earlier, as its market share stayed flat at 16.2%.

Sainsbury's blue-chip peers, whose sales Kantar said were lower, ended heavily in the red, with Tesco and Wm Morrison Supermarkets down 4.3% and 4.5%, respectively.

In the FTSE 250, IG Group Holdings led the mid-cap gainers, up 2.6% after it said its revenue increased substantially in the first quarter against a weak comparative, but said the volatile market conditions make it difficult to predict an outcome for the full year.

The spread betting and contracts-for-difference company, which gives retail traders access to financial markets, said it is trading in line with its expectations at present, with revenue in the first quarter to the end of August up 24% to GBP106.0 million, though it noted the same period last year was "particularly subdued".

Meanwhile, US-focused science and technology development and commercialisation company Allied Minds ended down 15%. Its shares dropped after New York-based hedge fund Kerrisdale Capital outlined the reasons for its short position in the London stock.

Kerrisdale said Allied Minds has "no objective evidence of commercial success" in its portfolio and said its review of the company's subsidiaries "indicates that they are developing products that are, at best, minor variations on existing alternatives, often in the face of significant competition and without plausible business models."

In the corporate calendar Wednesday, Smiths Group releases full-year results, United Utilities issues a trading statement, and Gresham House publishes half-year results. Meanwhile, Pan African Resources releases full-year results, while Highland Gold Mining and Styles&Wood Group publish half-year results.

In the economic calendar, China's Caixin manufacturing Purchasing Manager's Index is due at 0245 BST. Germany's manufacturing and services PMI are expected at 0830 BST, while the same for the eurozone are due at 0900 BST. European Central Bank President Mario Draghi speaks at the European Parliament in Brussels at 1400 BST.

In the US, Markit manufacturing PMI is due at 1445 BST, while Energy Information Administration crude oil stocks are at 1530 BST. Atlanta Federal Reserve President Dennis Lockhart speaks at 1730 BST before the Columbus Rotary Club in the state of Georgia.

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.